Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa

Natasha Croome, Monisha Ahluwalia, Lyndsay D. Hughes, M. Abas
{"title":"Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa","authors":"Natasha Croome, Monisha Ahluwalia, Lyndsay D. Hughes, M. Abas","doi":"10.1097/QAD.0000000000001416","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to identify the range and frequency of patient-reported barriers and facilitators to antiretroviral treatment (ART) adherence in sub-Saharan Africa (SSA). Design: Studies from 2005 to 2016 were identified by searching 10 electronic databases and through additional hand and web-searching. Methods: Inclusion criteria were HIV-positive adults taking ART based in any SSA country, qualitative study or quantitative survey and included at least one patient-reported barrier or facilitator to ART adherence. Exclusion criteria were only including data from treatment-naive patients initiating ART, only single-dose treatment, participants residing outside of SSA and reviews. Results: After screening 11 283 records, 154 studies (161 papers) were included in this review. Forty-three barriers and 30 facilitators were reported across 24 SSA countries. The most frequently identified barriers across studies were forgetting (n = 76), lack of access to adequate food (n = 72), stigma and discrimination (n = 68), side effects (n = 67) and being outside the house or travelling (n = 60). The most frequently identified facilitators across studies were social support (n = 60), reminders (n = 55), feeling better or healthier after taking ART (n = 35), disclosing their HIV status (n = 26) and having a good relationship with a health provider (n = 22). Conclusion: This review addresses the gap in knowledge by collating all the patient-reported barriers and facilitators to ART adherence in SSA. Current barriers measures need to be adapted or new tools developed to include the wide variety of factors identified. The factors that have the greatest impact need to be isolated so interventions are developed that reduce the barriers and enhance the facilitators.","PeriodicalId":355297,"journal":{"name":"AIDS (London, England)","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"120","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000001416","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 120

Abstract

Objective: The aim of this study was to identify the range and frequency of patient-reported barriers and facilitators to antiretroviral treatment (ART) adherence in sub-Saharan Africa (SSA). Design: Studies from 2005 to 2016 were identified by searching 10 electronic databases and through additional hand and web-searching. Methods: Inclusion criteria were HIV-positive adults taking ART based in any SSA country, qualitative study or quantitative survey and included at least one patient-reported barrier or facilitator to ART adherence. Exclusion criteria were only including data from treatment-naive patients initiating ART, only single-dose treatment, participants residing outside of SSA and reviews. Results: After screening 11 283 records, 154 studies (161 papers) were included in this review. Forty-three barriers and 30 facilitators were reported across 24 SSA countries. The most frequently identified barriers across studies were forgetting (n = 76), lack of access to adequate food (n = 72), stigma and discrimination (n = 68), side effects (n = 67) and being outside the house or travelling (n = 60). The most frequently identified facilitators across studies were social support (n = 60), reminders (n = 55), feeling better or healthier after taking ART (n = 35), disclosing their HIV status (n = 26) and having a good relationship with a health provider (n = 22). Conclusion: This review addresses the gap in knowledge by collating all the patient-reported barriers and facilitators to ART adherence in SSA. Current barriers measures need to be adapted or new tools developed to include the wide variety of factors identified. The factors that have the greatest impact need to be isolated so interventions are developed that reduce the barriers and enhance the facilitators.
撒哈拉以南非洲患者报告的抗逆转录病毒依从性障碍和促进因素
目的:本研究的目的是确定撒哈拉以南非洲(SSA)患者报告的抗逆转录病毒治疗(ART)依从性障碍和促进因素的范围和频率。设计:通过检索10个电子数据库以及额外的手工和网络检索,确定2005年至2016年的研究。方法:纳入标准是在任何SSA国家接受抗逆转录病毒治疗的hiv阳性成人,进行定性研究或定量调查,并包括至少一个患者报告的抗逆转录病毒治疗依从性障碍或促进因素。排除标准仅包括首次接受ART治疗的患者、单剂量治疗、居住在SSA以外的参与者和综述的数据。结果:在筛选了11 283份记录后,154项研究(161篇论文)被纳入本综述。据报告,在24个撒哈拉以南非洲国家中有43个障碍和30个促进者。研究中最常见的障碍是遗忘(n = 76),无法获得足够的食物(n = 72),耻辱和歧视(n = 68),副作用(n = 67)以及外出或旅行(n = 60)。在所有研究中,最常见的促进因素是社会支持(n = 60)、提醒(n = 55)、服用抗逆转录病毒治疗后感觉更好或更健康(n = 35)、披露其艾滋病毒状况(n = 26)以及与卫生服务提供者保持良好关系(n = 22)。结论:本综述通过整理所有患者报告的SSA坚持抗逆转录病毒治疗的障碍和促进因素,解决了知识上的差距。需要调整现有的壁垒措施或开发新的工具,以包括所确定的各种因素。需要隔离影响最大的因素,以便制定干预措施,减少障碍并加强促进因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信